Hypertension in the lungs is a relatively rare but very serious disease that is usually fatal within two years if left ...

Researchers have uncovered the pivotal role of a previously overlooked protein in the development of the serious illness. Hypertension in the lungs is a relatively rare but very serious disease that ...

PHocus enrollment completed in under 12 months from first patient dosed, representing a rapid enrollment pace in pulmonary hypertension ...

Can a one-minute sit-to-stand test predict long-term outcomes in pulmonary hypertension? New data suggest it can. Read more.

Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries that go from your heart to your lungs. It happens when these arteries become narrow or blocked, making it harder ...

In the 1980s, when Stella Kourembanas, MD, began her career in neonatology, she cared for newborns with pulmonary hypertension, a disease that results in abnormally high blood pressure in the lung ...

As the world marks Rare Disease Month, health experts are urging greater awareness of conditions that often go unnoticed ...

Pulmonary arterial hypertension (PAH) is a rare condition that's difficult to treat. The hallmarks of the disease—narrowing of the arterioles and capillaries that deliver blood to the lungs—force the ...

Please provide your email address to receive an email when new articles are posted on . Pulmonary hypertension appears in 25% to 30% of patients with COPD. There are no approved therapies for patients ...

I woke up one morning and couldn't walk. I looked at my husband and said, "I need to go to the hospital." ...

Significant predictors of 28-day mortality in critically ill patients with systemic sclerosis include male sex and BMI.

Winrevair, also known as sotatercept-csrk, is a medicine used to treat pulmonary arterial hypertension (PAH), which causes high blood pressure in the arteries that go from your heart to your lungs.